Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
0.347
-0.074 (-17.56%)
Apr 29, 2026, 12:36 PM EDT - Market open
Soligenix Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
3.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 60 Degrees Pharmaceuticals | 1.41M |
| SciSparc | 1.31M |
| VivoSim Labs | 142.00K |
| AIM ImmunoTech | 88.00K |
| Azitra | 7.50K |
| Pulmatrix | 3.00K |
SNGX News
- 1 day ago - Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 27 days ago - Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - PRNewsWire
- 4 weeks ago - Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - PRNewsWire
- 4 weeks ago - Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - PRNewsWire
- 5 weeks ago - HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - PRNewsWire
- 5 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. - GlobeNewsWire
- 5 weeks ago - Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" - PRNewsWire
- 7 weeks ago - Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - PRNewsWire